In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 4, 2007, Pages 802-810

  Garnier, Tracy ^a,e   Mäntylä, Antti ^b   Järvinen, Tomi ^b   Lawrence, Jayne ^c   Brown, Marc ^c   Croft, Simon ^a,d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Drugs for Neglected Diseases Initiative   (Switzerland)

^e UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Chemotherapy; Cutaneous; Leishmaniasis; Visceral naphthoquinones

Indexed keywords

3 PHOSPHONOOXYMETHYLBUPARVAQUONE; ANTILEISHMANIAL AGENT; BUPARVAQUONE; BUPARVAQUONE 3 PHOSPHATE; EXCIPIENT; PRODRUG; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; EMULSION; HISTOPATHOLOGY; IN VIVO STUDY; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LIVER PARENCHYMA; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; CHEMISTRY, PHARMACEUTICAL; FEMALE; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; NAPHTHOQUINONES; PRODRUGS; SKIN;

EID: 34548783789     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm303     Document Type: Article

References (33)

1. Desjeux P. Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27: 305-18.
2. Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 2001; 45: 2185-97.
3. Croft SL, Coombs GH. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19: 502-8.
4. Berman JD. Recent developments in leishmaniasis: Epidemiology, diagnosis, and treatment. Curr Infect Dis Rep 2005; 7: 33-8.
5. Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28: 42-51.
6. Murray HW, Berman JD, Davies CR et al. Advances in leishmaniasis. Lancet 2005; 366: 1561-77.
7. Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 2002; 3: 538-44.
8. Alkhawajah AM, Larbi E, al-Gindan Y et al. Treatment of cutaneous leishmaniasis with antimony: Intramuscular versus intralesional administration. Ann Trop Med Parasitol 1997; 91: 899-905.
9. El-On J, Livshin R, Even-Paz Z et al. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1986; 87: 284-8.
10. Soto J, Hernandez N, Mejia H et al. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/ methylbenzethonium chloride and injectable meglumine antimonate. Clin Infect Dis 1995; 20: 47-5.
11. Ben Salah A, Zakraoui H, Zaatour A et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995; 53: 162-6.
12. Asilian A, Jalayer T, Whitworth JA et al. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995; 53: 648-51.
13. Croft SL, Hogg J, Gutteridge WE et al. The activity of hydroxynaphthoquinones against Leishmania donovani. J Antimicrob Chemother 1992; 30: 827-32.
14. Mantyla A, Garnier T, Rautio J et al. Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. J Med Chem 2004; 47: 188-95.
15. Garnier T, Mantyla A, Jarvinen T et al. Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis. J Pharm Pharmacol 2007; 51: 41-9.
16. Wade A, Weller PJ. Handbook of Pharmaceutical Excipients. London: Pharmaceutical Society of Great Britain, 1994
17. Yardley V, Croft SL. Animal models of cutaneous leishmaniasis. In: Sande M, Zak O, eds. Handbook of Animal Models of Infection. London: Academic Press, 1999; 775-81.
18. Stauber LA, Franchino EM, Grun J. An eight-day method for screening compounds against Leishmania donovani in golden hamster. J Protozool 1958; 5: 269-73.
19. Neal RA. Experimental chemotherapy. In: Peters W, Killick-Kendrick R, eds. The Leishmaniases in Biology and Medicine. London: Academic Press, 1987; 794-845.
20. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000; 13 243-8.
21. Kropf P, Etges R, Schopt L et al. Characterísation of T cell-mediated responses in nonhealing and healing Leishmania major infections in the absence of endogenous IL-4. J Immunol 1997; 159: 3434-43
22. da Silva R, Sacks DL. Metacyclogenesis is a major determinant of Leishmania promastigote virulence and attenuation. Infect Immun 1987; 55: 2802-6.
23. Neal RA, Murphy AG, Olliaro P et al. Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1994; 88: 223-5.
24. Nicholas L, Prina E, Lang T et al. Reall-time PCR for detection and quantitation of Leishmania in mouse tissues. J Clin Microbiol 2002; 40: 1666-9.
25. Kropf P, Muller I, Brunson K. The leishmaniasis model. In: Kaufmann SHE, Kabelitz D, eds. Immunology of Infection. Series: Methods in Miciobiology, 32. London: Academic Press, 2002; 419-58.
26. Titus RG, Marchand M, Boon T et al. A limitting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 1985; 7: 545-55.
27. Taswell C. Limiting dilution assays for the separation, characterization and quantitation of biologically active particles and their clonal progeny. In: Pretlow, TG, Pretlow, TP, eds. Cell Separation: Methods and Selected Applications. London: Academic Press, 1087; 109-45.
28. El-On J, Jacobs GP. Compositions and methods for topical treatment of cutaneous leishmaniasis with paromomycin. US patent 4,505,901, 1985.
29. Laskay T, Diefenbach A, Rollinghoff M et al. Early parasite containment is decisive for resistance to Leishmania major Infection. Eur J Immunol 1995; 25: 2220-7.
30. Bretscher PA, Wei G, Menon JN et al. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 1992; 257: 539-42.
31. Rogers KA, DeKrey GK, Mbow ML et al. Type 1 and type 2 responses to Leishmania major. FEMS Microbiol Lett 2002; 209: 1-7.
32. Bagley DM, Gardner JR, Holland G et al. Skin irritation: Reference chemicals data bank. Toxicol In Vitro 1996; 10: 1-6.
33. Philips CA, Michniak BB. Topical application of Azone analogs to hairless mouse skin: A histopathological study. Int J Pharm 1995; 125: 63-71.